[CAS NO. 332348-12-6] Abatacept

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [332348-12-6]

Catalog

HY-108829

Brand

MCE

CAS

332348-12-6

DESCRIPTION [332348-12-6]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Abatacept]

For research use only. We do not sell to patients.

Summary

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) ^[1] . Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases ^[2] .

In Vivo

Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t _obs = 2.50) paw edema reduction compared with the IV dose group ^[2] .
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V _ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7% ^[2] .
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2 ^–/– BALB/c (H-2d/d) mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g ^[2]
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:	IV or SC
Result:	Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t _obs = 2.50) paw edema reduction compared with the IV dose group.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g ^[2]
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
Administration:	IV or SC
Result:	The NCA clearance (CL) is 20.8 mL/day/kg, volume (V _ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00409838	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2007	Phase 3
NCT00277225	Bristol-Myers Squibb	Psoriasis Vulgaris	November 1995	Phase 1
NCT01315938	Karolinska Institutet\|Institute of Rheumatology, Prague\|King´s College Hospital NHS Trust	Polymyositis\|Dermatomyositis	January 2011	Phase 2
NCT01299961	University of California, Los Angeles	Rheumatoid Arthritis	March 2011	Phase 3
NCT04610476	University of Erlangen-Nürnberg Medical School	Psoriatic Arthritis\|Withdrawal\|Reduction	October 19, 2020	Phase 3
NCT03882008	University of Washington\|Bristol-Myers Squibb	Rheumatoid Arthritis	May 23, 2019	Phase 4
NCT00886795	Johns Hopkins University\|Bristol-Myers Squibb	Urticaria	May 2009	Phase 1\|Phase 2
NCT01999868	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Psoriasis	March 19, 2014	Phase 2
NCT01773707	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Juvenile Diabetes Research Foundation	Abnormal Glucose Tolerance\|Type 1 Diabetes	March 2013	Phase 2
NCT02652273	NHS Greater Glasgow and Clyde\|University of Glasgow	Arthritis, Rheumatoid	January 2016	Phase 4
NCT04872218	Philippe Bégin\|Centre hospitalier de l´Université de Montréal (CHUM)\|St. Justine´s Hospital	Peanut Allergy	March 1, 2022	Phase 2
NCT01890473	Bristol-Myers Squibb	Rheumatoid Arthritis	July 2013	Phase 1
NCT01743131	Boston Children´s Hospital\|FDA Office of Orphan Products Development	Graft vs Host Disease\|Malignancy	February 2013	Phase 2
NCT04255134	St George´s, University of London	Rheumatoid Arthritis	September 7, 2020	Phase 4
NCT01439204	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2011	Phase 1
NCT01758198	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Rheumatoid Arthritis	April 11, 2013	Phase 4
NCT02353780	Dr. Larry W. Moreland\|Genentech, Inc.\|Bristol-Myers Squibb\|University of Pittsburgh	Rheumatoid Arthritis (RA)	March 2015	Phase 4
NCT01860976	Bristol-Myers Squibb	Psoriatic Arthritis	June 17, 2013	Phase 3
NCT02078882	Christopher Bowlus, MD\|Bristol-Myers Squibb\|University of California, Davis	Primary Biliary Cirrhosis	September 2014	Phase 4
NCT00430677	Bristol-Myers Squibb	Systemic Lupus Erythematosus	June 2007	Phase 2\|Phase 3
NCT00442611	Stanford University\|Bristol-Myers Squibb	Scleroderma, Diffuse\|Scleroderma, Systemic	November 2008	Phase 1\|Phase 2
NCT00048581	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2002	Phase 3
NCT00162279	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2000	Phase 2
NCT03619876	Columbia University\|Bristol-Myers Squibb	Rheumatoid Arthritis\|Myocardial Inflammation	July 10, 2019	Phase 4
NCT02722694	Jiangsu Simcere Pharmaceutical Co., Ltd.\|Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	August 2016	Phase 3
NCT00279760	Bristol-Myers Squibb	Rheumatoid Arthritis		Phase 1\|Phase 2
NCT01917058	Columbia University	Alopecia Areata	August 2013	Phase 2
NCT04106804	University of Erlangen-Nürnberg Medical School	Evaluate Bone Changes in Patients With PsA	June 6, 2018	Phase 4
NCT02557100	Bristol-Myers Squibb	Rheumatoid Arthritis	November 19, 2015	Phase 4
NCT02592798	Bristol-Myers Squibb	Nephrotic Syndrome\|Focal Segmental Glomerulosclerosis\|Minimal Change Disease	March 9, 2016	Phase 2
NCT05080218	Jeffrey Curtis\|University of Alabama at Birmingham\|University of Nebraska\|University of Pennsylvania\|AbbVie\|Bristol-Myers Squibb\|Novartis\|Eli Lilly and Company\|Pfizer\|Foundation for Advancing Science Technology Education and Research	Rheumatoid Arthritis\|Psoriatic Arthritis\|Spondylarthritis	November 15, 2021	Phase 4
NCT00534313	Bristol-Myers Squibb	Psoriatic Arthritis	November 2007	Phase 2
NCT03669861	Massachusetts General Hospital\|Bristol-Myers Squibb	IgG4-related Disease	November 13, 2018	Phase 2
NCT04449224	Hanyang University\|Ministry of Health, Republic of Korea	Rheumatoid Arthritis	April 27, 2020
NCT02840175	Assistance Publique - Hôpitaux de Paris	Juvenile Idiopathic Arthritis	May 18, 2017	Phase 3
NCT04572620	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Interstitial Lymphocytic Lung Disease	September 7, 2020
NCT01279954	Oregon Health and Science University\|Bristol-Myers Squibb	Uveitis	January 2012	Phase 2
NCT01001832	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2009	Phase 2\|Phase 3
NCT01351480	Arthritis & Rheumatic Disease Specialties Research\|Bristol-Myers Squibb	Rheumatoid Arthritis	June 2011	Phase 3
NCT04871191	Assistance Publique - Hôpitaux de Paris\|URC-CIC Paris Descartes Necker Cochin	Granulomatosis With Polyangiitis\|Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis	October 2022	Phase 2
NCT05335928	Massachusetts General Hospital\|Bristol-Myers Squibb	Myocarditis Acute\|Cancer	June 22, 2022	Phase 3
NCT04946669	The First Affiliated Hospital with Nanjing Medical University\|National Natural Science Foundation of China	Dermatomyositis\|Abatacept	February 1, 2021	Early Phase 1
NCT03059888	Johns Hopkins University\|Bristol-Myers Squibb	Myasthenia Gravis	April 12, 2017	Early Phase 1
NCT00124449	Bristol-Myers Squibb	Arthritis, Rheumatoid	February 2005	Phase 2
NCT00306878	Bristol-Myers Squibb	Psoriasis Vulgaris	August 1995	Phase 1
NCT01693640	NYU Langone Health\|Bristol-Myers Squibb	Female Patients With Behcet´s Syndrome	June 2012	Early Phase 1
NCT01173120	Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	November 2009	Phase 3
NCT02281058	Brigham and Women´s Hospital\|Bristol-Myers Squibb	Vitiligo	January 2015	Phase 1
NCT03457142	Roswell Park Cancer Institute\|Bristol-Myers Squibb	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	September 11, 2018	Phase 2
NCT04120831	University of Erlangen-Nürnberg Medical School	Rheumatoid Arthritis	October 7, 2019	Phase 2
NCT01954979	Beth Israel Deaconess Medical Center\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	Chronic Graft Versus Host Disease	October 2013	Phase 1
NCT03414502	University of Nebraska	Rheumatoid Arthritis	August 2007	Phase 3
NCT01116427	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Multiple Sclerosis, Relapsing-Remitting	September 2010	Phase 2
NCT02867800	Monica Bhatia\|Columbia University	Sickle Cell Disease\|Graft Versus Host Disease	July 2016	Phase 1
NCT04377867	Marmara University\|The Scientific and Technological Research Council of Turkey	LRBA Deficiency\|CTLA4 Haploinsufficiency	January 15, 2020
NCT04203875	Stuart Knechtle, M.D.\|Duke University	Autoimmune Hepatitis	March 9, 2020	Phase 1
NCT00345748	Bristol-Myers Squibb	Rheumatoid Arthritis	June 2006	Phase 2
NCT00162201	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2003	Phase 1
NCT03215927	Rohit Aggarwal, MD\|Bristol-Myers Squibb\|University of Pittsburgh	Myositis\|Interstitial Lung Disease	June 1, 2017	Phase 2
NCT05428488	University Hospital, Montpellier	Rheumatoid Arthritis	September 2022	Phase 3
NCT01844518	Bristol-Myers Squibb	Active Polyarticular Juvenile Idiopathic Arthritis	August 30, 2013	Phase 3
NCT01142726	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2010	Phase 3
NCT02915159	Bristol-Myers Squibb	Sjogrens Disease	December 6, 2016	Phase 3
NCT02805010	Jiangsu Simcere Pharmaceutical Co., Ltd.\|Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	October 2016	Phase 1
NCT04474847	University of Pennsylvania	Giant Cell Arteritis	March 15, 2021	Phase 3
NCT01272856	Benaroya Research Institute\|Bristol-Myers Squibb	Relapsing Polychondritis	January 2011	Phase 1
NCT01846975	Rüdiger B. Müller\|Bristol-Myers Squibb\|Cantonal Hospital of St. Gallen	Rheumatoid Arthritis	May 2013	Phase 4
NCT03632187	University Hospital, Brest\|Bristol-Myers Squibb	Polymyalgia Rheumatica	December 13, 2018	Phase 3
NCT02270957	Oklahoma Medical Research Foundation\|Bristol-Myers Squibb	Systemic Lupus Erythematosus	January 2014	Phase 2
NCT05195645	Assistance Publique - Hôpitaux de Paris	Myocarditis	October 4, 2022	Phase 2
NCT05289167	NYU Langone Health	Graft-versus-host Disease	March 13, 2022	Phase 1\|Phase 2
NCT05426252	The Hospital for Sick Children\|Thalassemia Foundation of Canada	Thalassemia in Children	March 22, 2022	Phase 1\|Phase 2
NCT03841357	Duke University	Juvenile Idiopathic Arthritis	October 29, 2019	Phase 3
NCT00533897	Bristol-Myers Squibb	Rheumatoid Arthritis	November 2007	Phase 3
NCT04529902	Brigham and Women´s Hospital\|National Institute on Aging (NIA)\|Rutgers University\|Johns Hopkins University	Rheumatoid Arthritis	August 17, 2020
NCT00559585	Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	January 2008	Phase 3
NCT04186871	Bristol-Myers Squibb	Autoimmune Disorder\|Rheumatoid Arthritis\|Systemic Lupus Erythematosus\|Primary Sjögren´s Syndrome	January 7, 2020	Phase 2
NCT01917708	Emory University	Hurler Syndrome\|Fanconi Anemia\|Glanzmann Thrombasthenia\|Wiskott-Aldrich Syndrome\|Chronic Granulomatous Disease\|Severe Congenital Neutropenia\|Leukocyte Adhesion Deficiency\|Shwachman-Diamond Syndrome\|Diamond-Blackfan Anemia\|Dyskeratosis-congenita\|Chediak-Higashi Syndrome\|Severe Aplastic Anemia\|Thalassemia Major\|Hemophagocytic Lymphohistiocytosis\|Sickle Cell Disease	January 2014	Phase 1
NCT03192969	Bristol-Myers Squibb	Giant Cell Arteritis	July 15, 2017	Phase 3
NCT05621759	NYU Langone Health	Graft Vs Host Disease	August 23, 2022	Phase 2
NCT03680092	Dimitrios Tzachanis, MD PhD\|Bristol-Myers Squibb\|University of California, San Diego	GVHD\|Hematologic Neoplasms	November 26, 2019	Phase 2
NCT05451615	Zhejiang Provincial People´s Hospital	Abatacept\|Treatment Compliance\|Rheumatoid Arthritis	September 30, 2022	Phase 3
NCT00663702	Bristol-Myers Squibb	Arthritis, Rheumatoid	May 2008	Phase 3
NCT01350804	Novartis Pharmaceuticals\|Novartis	Rheumatoid Arthritis	September 2011	Phase 3
NCT03669367	Fundacion Clinic per a la Recerca Biomédica	Palindromic Rheumatism, Wrist	April 1, 2019	Phase 4
NCT04529863	Brigham and Women´s Hospital\|National Institute on Aging (NIA)\|Rutgers University\|Johns Hopkins University	Rheumatoid Arthritis	August 17, 2020
NCT04118153	Carla Greenbaum, MD\|Juvenile Diabetes Research Foundation\|Medical College of Wisconsin\|Benaroya Research Institute	Type 1 Diabetes	March 5, 2021	Early Phase 1
NCT01314495	Julian M. Mackay-Wiggan\|Columbia University	Alopecia Totalis+Universalis	September 2011	Phase 2
NCT02053727	University of California, Los Angeles	Rheumatoid Arthritis\|Chronic Hepatitis B	July 2014	Not Applicable
NCT00406653	Bristol-Myers Squibb	Crohn´s Disease	December 2006	Phase 3
NCT02232880	Vanderbilt University Medical Center\|Bristol-Myers Squibb	Hypertension	August 2014	Phase 2
NCT02598466	Bristol-Myers Squibb\|Hexor, South Africa	Rheumatoid Arthritis	July 2015
NCT00122382	Bristol-Myers Squibb	Rheumatoid Arthritis	July 2005	Phase 3
NCT00277199	Bristol-Myers Squibb	Healthy Subjects	September 2002	Phase 1
NCT00705367	Bristol-Myers Squibb	Lupus Nephritis	August 2008	Phase 1
NCT03737708	Astellas Pharma Korea, Inc.\|Astellas Pharma Inc	Rheumatoid Arthritis (RA)	February 13, 2019	Phase 4
NCT02027298	The Cleveland Clinic\|Bristol-Myers Squibb	Primary Sjogren´s Syndrome\|Secondary Sjogren´s Syndrome\|Inflammatory Arthritis\|Rheumatoid Arthritis	November 2013	Phase 2
NCT00119678	Bristol-Myers Squibb	Systemic Lupus Erythematosus	September 2005	Phase 2
NCT04686929	The First Affiliated Hospital of Soochow University	Abatacept\|Acute-graft-versus-host Disease\|Haplo-identical HCT\|Prevention	June 1, 2021	Phase 1\|Phase 2
NCT00558506	Charite University, Berlin, Germany\|Bristol-Myers Squibb	Ankylosing Spondylitis	January 2008	Phase 2
NCT02778906	University of Erlangen-Nürnberg Medical School\|Bristol-Myers Squibb	Arthralgia\|Arthritis	November 2014	Phase 3
NCT04909801	Bristol-Myers Squibb	Rheumatoid Arthritis	September 15, 2021	Phase 3
NCT00989235	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2007	Phase 3
NCT02971683	Bristol-Myers Squibb	Polymyositis\|Dermatomyositis\|Autoimmune Necrotizing Myopathy\|Overlap Myositis\|Juvenile Myositis Above the Age of 18	May 4, 2017	Phase 3
NCT02594735	George Washington University	Dermatomyositis	November 2015	Phase 4
NCT04472494	Bristol-Myers Squibb	COVID-19\|SARS-CoV-2	October 14, 2020	Phase 2
NCT04529876	Brigham and Women´s Hospital\|National Institute on Aging (NIA)\|Rutgers University\|Johns Hopkins University	Rheumatoid Arthritis	August 17, 2020
NCT01295151	Julia Brown\|University of Leeds	Rheumatoid Arthritis	August 2011	Phase 4
NCT04955366	Emory University	Renal Transplant Recipient	September 22, 2021	Phase 2
NCT00162266	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2000	Phase 2
NCT02108860	University of South Florida\|The Cleveland Clinic\|Bristol-Myers Squibb\|University of Pennsylvania\|National Institutes of Health (NIH)\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Granulomatosis With Polyangiitis (Wegener´s)\|Granulomatosis With Polyangiitis\|Wegener´s Granulomatosis\|ANCA-Associated Vasculitis	April 25, 2015	Phase 3
NCT00124982	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2005	Phase 3
NCT03784261	Shinshu University	Rheumatoid Arthritis	December 17, 2018	Phase 2
NCT04380740	Boston Children´s Hospital\|Bristol-Myers Squibb	Graft Vs Host Disease	March 30, 2022	Phase 2
NCT00276250	Emory University\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	December 2005	Phase 2
NCT03929601	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health (NIH)\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	February 17, 2020	Phase 2
NCT05303272	Tongji Hospital\|Wuhan Central Hospital\|Wuhan Hospital of Traditional Chinese Medicine	Pemphigus Vulgaris	February 1, 2021	Phase 4
NCT00048932	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2002	Phase 3
NCT00739960	University of Chicago\|Bristol-Myers Squibb	Sarcoidosis	August 2008	Phase 2
NCT02067910	University Medical Center Groningen\|Bristol-Myers Squibb	Sjögren´s Syndrome	August 2014	Phase 3
NCT00767325	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2008	Phase 3
NCT03924401	Emory University\|Thrasher Research Fund\|Sickle Cell Transplant Advocacy & Research Alliance (STAR)\|Aflac Cancer and Blood Disorders Center\|Bristol-Myers Squibb	Graft Versus Host Disease	August 22, 2019	Phase 2
NCT00095147	Bristol-Myers Squibb	Rheumatoid Arthritis	February 2005	Phase 3
NCT02169544	Bristol-Myers Squibb	Rheumatoid Arthritis	January 31, 2014
NCT01221636	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2010	Phase 1
NCT02429934	University of California, Los Angeles\|Bristol-Myers Squibb	Systemic Lupus Erythematosus Arthritis	October 2015	Phase 1\|Phase 2
NCT01339481	Astellas Pharma Inc\|Perseid Therapeutics LLC	Rheumatoid Arthritis	February 2011
NCT00929864	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2009	Phase 3
NCT00279734	Bristol-Myers Squibb	Rheumatoid Arthritis	August 2004	Phase 1
NCT02018042	Columbia University\|Bristol-Myers Squibb	Alopecia Areata	September 2013	Phase 2
NCT00547521	Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	December 2007	Phase 3
NCT00482066	Imperial College London\|Bristol-Myers Squibb	ANCA-associated Vasculitis	November 2007	Phase 2
NCT02547493	University Hospital, Montpellier\|Bristol-Myers Squibb	Rheumatoid Arthritis	March 3, 2016	Not Applicable
NCT03492658	Leiden University Medical Center	Rheumatoid Arthritis\|Rheumatic Diseases	May 17, 2018	Phase 4
NCT01333878	Orrin M Troum, M.D. and Medical Associates\|Bristol-Myers Squibb	Rheumatoid Arthritis	March 2011	Phase 2\|Phase 3
NCT00420199	Bristol-Myers Squibb	Active Rheumatoid Arthritis	May 2007	Phase 3
NCT04477642	Beth Israel Deaconess Medical Center\|Boston Children´s Hospital\|Bristol-Myers Squibb\|Brigham and Women´s Hospital	COVID-19	August 2020	Phase 1\|Phase 2
NCT00774852	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Lupus Nephritis\|Lupus Erythematosus, Systemic	November 2008	Phase 2
NCT00287547	Bristol-Myers Squibb	Psoriasis Vulgaris	March 1997	Phase 2
NCT02161406	Dinesh Khanna, MD, MS\|Bristol-Myers Squibb\|National Institute of Allergy and Infectious Diseases (NIAID)\|University of Michigan	Diffuse Cutaneous Systemic Sclerosis	September 2014	Phase 2
NCT00410410	Bristol-Myers Squibb	Ulcerative Colitis	December 2006	Phase 3
NCT00556439	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|The Cleveland Clinic\|Office of Rare Diseases (ORD)\|Rare Diseases Clinical Research Network	Takayasu´s Arteritis\|Giant Cell Arteritis	December 2008	Phase 2
NCT00468208	University of Pennsylvania\|Office of Rare Diseases (ORD)\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|Rare Diseases Clinical Research Network	Wegener´s Granulomatosis	February 2008	Phase 1\|Phase 2
NCT05170672	Bristol-Myers Squibb
NCT02037737	Bristol-Myers Squibb	Rheumatoid Arthritis	September 30, 2016
NCT00254293	Bristol-Myers Squibb	Rheumatoid Arthritis	January 2006	Phase 1\|Phase 2
NCT03652961	NYU Langone Health\|Dartmouth-Hitchcock Medical Center\|Bristol-Myers Squibb	Rheumatoid Arthritis	June 2, 2019	Phase 4
NCT00048568	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2002	Phase 3
NCT00035529	Bristol-Myers Squibb	Multiple Sclerosis	November 2001	Phase 2
NCT02109666	Bristol-Myers Squibb	Rheumatoid Arthritis	March 2008
NCT01012492	Boston Children´s Hospital	AML\|ALL\|Undifferentiated Leukemia\|Biphenotypic Leukemia\|Refractory Anemia\|Refractory Anemia With Ringed Sideroblasts\|Refractory Cytopenia With Multilineage Dysplasia\|Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts\|Refractory Anemia With Excess Blasts-1 (5-10% Blasts)\|Refractory Anemia With Excess Blasts-2 (10-20% Blasts)\|Myelodysplastic Syndrome, Unclassified\|MDS Associated With Isolated Del (5q)	November 2009	Phase 2
NCT01844895	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2013	Phase 3
NCT04344873	University of Utah\|National Institute on Aging (NIA)	Cardiovascular Diseases\|Inflammation\|Aging	November 30, 2022	Early Phase 1
NCT01555879	Arthritis Northwest PLLC\|Bristol-Myers Squibb	Arthritis, Rheumatoid	March 2012
NCT04925375	Children´s Hospital Medical Center, Cincinnati\|Bristol-Myers Squibb	Interstitial Lung Disease\|Common Variable Immunodeficiency	July 14, 2021	Phase 2
NCT01714817	Bristol-Myers Squibb	Lupus Nephritis	January 22, 2013	Phase 3
NCT04593940	Daniel Benjamin\|National Center for Advancing Translational Sciences (NCATS)\|Biomedical Advanced Research and Development Authority\|Duke University	Covid19	October 15, 2020	Phase 3
NCT00484289	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2006	Phase 3
NCT03733067	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	CTLA4 Haploinsufficency\|Chronic Cytopenia	November 28, 2022	Phase 1\|Phase 2
NCT00095173	Bristol-Myers Squibb	Juvenile Rheumatoid Arthritis	December 2003	Phase 3
NCT03086343	AbbVie	Rheumatoid Arthritis (RA)	May 9, 2017	Phase 3
NCT03084419	Cambridge University Hospitals NHS Foundation Trust\|Bristol-Myers Squibb	Rheumatoid Arthritis\|Interstitial Lung Disease	June 26, 2018	Phase 2
NCT01835470	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Juvenile Idiopathic Arthritis	August 9, 2013	Phase 3
NCT00784459	Washington University School of Medicine\|Bristol-Myers Squibb	Atopic Asthma	October 2008	Phase 2
NCT03440892	Vastra Gotaland Region	Rheumatoid Arthritis	November 1, 2017
NCT03871361	Universitaire Ziekenhuizen KU Leuven\|Ziekenhuis Netwerk Antwerpen (ZNA)	Eye Diseases\|Uveitis	April 1, 2019	Phase 2
NCT03227419	Lille Catholic University	Arthritis, Rheumatoid	January 22, 2018	Phase 4
NCT03714022	Bristol-Myers Squibb	Rheumatoid Arthritis	November 9, 2018	Phase 1
NCT01557374	Assistance Publique - Hôpitaux de Paris\|Ministry of Health, France	Rheumatoid Arthritis	April 2012	Phase 4
NCT02504268	Bristol-Myers Squibb	Rheumatoid Arthritis	September 3, 2015	Phase 3

Appearance

Solid

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.